The Pharmacy Times® Ovarian Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to the group of diseases that originates in the ovaries, fallopian tubes, or the peritoneum.
March 22nd 2024
The treatment is indicated for patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
FDA Approves FoundationOne Liquid CDx for Breast, Ovarian, Lung Cancer Indications
October 28th 2020FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.
Read More